Opyl Limited

Equities

OPL

AU0000070856

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 02:10:44 2024-04-26 am EDT			5-day change	1st Jan Change
0.016 ^AUD	-23.81%		-15.79%	-42.86%

Apr. 23	Opyl to Divest Opin Business	MT
Mar. 22	Opyl Receives Offer for Patient Recruitment Business	MT

Opyl Limited Provides Earnings Guidance for the Fiscal Second Half of 2023

February 26, 2023 at 05:57 pm EST

Opyl Limited provided earnings guidance for the fiscal second half of 2023. Opyl is also anticipating further revenue contract wins stemming from these MSAs and other opportunities in the sales pipeline, which implies a stronger 2HFY23 for the Company.

Latest news about Opyl Limited

Opyl to Divest Opin Business	Apr. 22	MT
Opyl Receives Offer for Patient Recruitment Business	Mar. 22	MT
Opyl Requests Trading Halt After Receiving Offer For Opin Business	Mar. 20	MT
Opyl Chair Stepping Down in End-April	Mar. 15	MT
Opyl Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Opyl Raises Nearly AU$900,000 from Rights Issue Shortfall Placement	Feb. 09	MT
Opyl Grows Cash Receipts for Fiscal Q2	Jan. 31	MT
Opyl Receives Commitments for Potential Shortfall	Jan. 02	MT
Opyl Appoints Interim CEO	Nov. 23	MT
Opyl Limited Appoints Saurabh Jain as Interim Chief Executive Officer	Nov. 23	CI
Opyl Secures R&D Tax Rebate for Fiscal Year 2023	23-09-22	MT
Opyl Limited Announces Appointment of Antanas Guoga as Director, Effective from September 4, 2023	23-09-05	CI
Opyl Limited Announces Board Update	23-09-03	CI
Opyl Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Opyl Limited Launches TrialKey MVP	23-08-23	CI
Opyl Limited Announces Senior Leadership Changes	23-07-05	CI
Opyl Limited Announces Resignation of Michelle Gallaher as CEO	23-07-05	CI
Opyl Limited Appoints Dr. Hugo Stephenson as Board Advisor	23-05-01	CI
Opyl Completes Issuance of Shortfall Shares	23-04-04	MT
Opyl Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26	CI
Opyl Limited Provides Earnings Guidance for the Fiscal Second Half of 2023	23-02-26	CI
Opyl Limited Announces Resignation of Julian Chick as Non-Executive Director	23-02-13	CI
Opyl Extends Rights Issue Closing Date	23-01-18	MT
IT Gains Push Australian Shares Higher Amid Mixed Trading	23-01-18	MT
Opyl Enters Master Services Agreement With Pharmaceutical Firm	23-01-18	MT

Chart Opyl Limited

Duration

Period

More charts

Company Profile

Opyl Limited is an Australia-based artificial intelligence (AI) company. The Company leverages data and technology to transform the landscape of clinical trials and medical research. It is a digital health company, specialized in leveraging artificial intelligence technologies to elevate clinical trial design and forecast outcomes, empowering clinical researchers, biopharmaceutical corporations, and medical investors to enhance trial design, drug development, and market delivery. Its Social Media Insights solution captures and analyses online public conversations from people living with a medical condition, healthcare professionals, carers, and researchers. Its TrialKey platform provides users access to tailored, actionable steps to address critical trial challenges, improving the likelihood of success. The Company is specialized in applying AI and predictive analytics to social media to accelerate therapy adoption and market development in the healthcare industry.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical Software & Technology Services

	1st Jan change	Capi.
OPYL LIMITED	-42.86%	1.77M
VEEVA SYSTEMS INC.	+4.36%	32.47B
PRO MEDICUS LIMITED	+14.14%	7.45B
SECTRA AB	+22.93%	3.89B
EVOLENT HEALTH, INC.	-16.29%	3.15B
OMNICELL, INC.	-25.96%	1.28B
LUNIT INC.	-36.14%	1.09B
B-SOFT CO.,LTD.	-35.42%	902M
SIMULATIONS PLUS, INC.	-0.13%	893M
VERADIGM INC.	-24.12%	857M

Medical Software & Technology Services